Stocksigma LogoStocksigma Logo

Novelix Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakh)

■ Revenue: 4,473 (+23.0% YoY | +21.2% QoQ) ■ EBITDA: 212 (+203.4% YoY | +63.5% QoQ) ■ EBITDA Margin (%): 4.7 (+282 bps YoY | +123 bps QoQ) ■ PAT: 156

Novelix Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakh)

Novelix Pharmaceuticals Ltd · Outcome · 12 Nov 2026, 12:52 am

Novelix Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakh) ■ Revenue: 4,473 (+23.0% YoY | +21.2% QoQ) ■ EBITDA: 212 (+203.4% YoY | +63.5% QoQ) ■ EBITDA Margin (%): 4.7 (+282 bps YoY | +123 bps QoQ) ■ PAT: 156 (+193.2% YoY | +32.6% QoQ) ■ EPS (INR): 0.57 (+16.3% YoY | +16.3% QoQ)

Original exchange filing (PDF)

More announcements from Novelix Pharmaceuticals Ltd

All Novelix Pharmaceuticals Ltd announcements